LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Puma Biotechnology Inc

Avatud

SektorTervishoid

3 -2.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.92

Max

3.04

Põhinäitajad

By Trading Economics

Sissetulek

-1M

19M

Müük

-21M

59M

P/E

Sektori keskmine

4.952

54.379

Aktsiakasum

0.43

Kasumimarginaal

32.678

Töötajad

172

EBITDA

-8.9M

18M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+42.43% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

17M

159M

Eelmine avamishind

5.28

Eelmine sulgemishind

3

Uudiste sentiment

By Acuity

11%

89%

12 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2025, 22:34 UTC

Omandamised, ülevõtmised, äriostud

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12. mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12. mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12. mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12. mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12. mai 2025, 22:43 UTC

Tulu

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12. mai 2025, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12. mai 2025, 22:07 UTC

Omandamised, ülevõtmised, äriostud

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12. mai 2025, 22:07 UTC

Omandamised, ülevõtmised, äriostud

Ampol to Sell Australia Retail Electricity Business to AGL

12. mai 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12. mai 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12. mai 2025, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12. mai 2025, 22:04 UTC

Omandamised, ülevõtmised, äriostud

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. mai 2025, 21:15 UTC

Peamised uudised

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12. mai 2025, 21:01 UTC

Tulu

Constellation Software 1Q Rev $2.65B >CSU.T

12. mai 2025, 21:01 UTC

Tulu

Constellation Software 1Q Net $115M >CSU.T

12. mai 2025, 21:01 UTC

Tulu

Constellation Software 1Q EPS $5.44 >CSU.T

12. mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. mai 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

12. mai 2025, 20:44 UTC

Peamised uudised

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12. mai 2025, 20:31 UTC

Peamised uudised

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12. mai 2025, 20:24 UTC

Tulu

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12. mai 2025, 20:24 UTC

Tulu

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12. mai 2025, 20:24 UTC

Peamised uudised

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12. mai 2025, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12. mai 2025, 20:15 UTC

Tulu

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12. mai 2025, 20:10 UTC

Tulu

Blink Charging 1Q Rev $20.8M >BLNK

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

42.43% tõus

12 kuu keskmine prognoos

Keskmine 4.33 USD  42.43%

Kõrge 7 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

1

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

12 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.